Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$12.56 USD

12.56
2,263,426

+0.25 (2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.56 0.00 (0.00%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More

by Urmimala Biswas

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Zacks Equity Research

ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

Zacks Equity Research

Integra (IART) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

Debanjana Dey headshot

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

by Debanjana Dey

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Zacks Equity Research

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Zacks Equity Research

Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.

Zacks Equity Research

Integra (IART) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.

Zacks Equity Research

Here's Why You Should Retain Integra LifeSciences (IART) Stock

by Zacks Equity Research

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.

Zacks Equity Research

Integra's (IART) Neurosurgery Rebounds Despite Supply Issues

by Zacks Equity Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

Zacks Equity Research

Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)

by Zacks Equity Research

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

Zacks Equity Research

Integra (IART) Down 3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe

by Zacks Equity Research

Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.

Zacks Equity Research

Integra (IART) Arms Grow Sequentially Despite Supply Issues

by Zacks Equity Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.

Zacks Equity Research

Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

Zacks Equity Research

Integra LifeSciences (IART) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings

by Zacks Equity Research

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

Zacks Equity Research

Integra (IART) Acquires Acell, Focuses on Regenerative Space

by Zacks Equity Research

The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.

Zacks Equity Research

Integra (IART) Preliminary Q4 Reported Sales Show Recovery

by Zacks Equity Research

Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.

Zacks Equity Research

NEOGEN (NEOG) Fortifies Global Position via Megazyme Buyout

by Zacks Equity Research

NEOGEN's (NEOG) buyout of Megazyme is expected to strengthen its Food Safety business worldwide.

Zacks Equity Research

Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.

Zacks Equity Research

Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake

by Zacks Equity Research

The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.

Zacks Equity Research

Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio

by Zacks Equity Research

Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.

Zacks Equity Research

Integra (IART) Sells Unprofitable Arm to Focus on Core Business

by Zacks Equity Research

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

Zacks Equity Research

Integra (IART) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Integra (IART) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

Zacks Equity Research

Integra (IART) to Buy ACell, Expand Regenerative Capability

by Zacks Equity Research

Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.